Connexus (neuroimplants)

History

2025: Product Announcement

On November 20, 2025, the American startup Paradromics, a developer of neurointerfaces, announced clinical trials of its Connexus system to restore speech in paralyzed patients. Connexus is positioned as the first high-performance fully implantable interface for long-term use.

According to New Atlas, Paradromics became the first company to receive approval for the use of fully implantable BCI (Brain-Computer Interface) to restore speech in people with paralysis.

𝓲

Фото: newatlas.com

The study will assess the safety and effectiveness of a device designed to communicate through text or synthesized speech, as well as computer control. The device is equipped with a titanium case and more than 400 microelectrodes for recording high-density neural signals.

Electrodes are implanted in the motor cortex of the brain. Data on the subcutaneous cable is transmitted to the chest implant, which communicates with the external receiver through a protected optical channel. The system uses AI algorithms to convert neural activity into speech or commands.

The study will begin with two participants. They will install electrodes in the speech centers of the brain. The system will learn by deciphering neural patterns that occur when phrases are mentally spoken. The key challenge is real-time speech synthesis using the patient's original voice. Additionally, they will study the possibility of controlling the computer cursor with the power of thought.

With successful results, the group will be expanded to 10 people. According to experts, the creation of fully implantable systems is a key step for the transition of neurointerfaces from laboratories to clinical practice.^[1]

Notes